Hormonal Management of Menopausal Symptoms in Women With a History of Gynecologic Malignancy

Benjamin S. Harris, MD, MPH; Katherine C. Bishop, MD; Jeffrey A. Kuller, MD; Anne C. Ford, MD; Lisa C. Muasher, MD, MPH; Sarah E. Cantrell, MLIS; Thomas M. Price, MD

Disclosures

Menopause. 2020;27(2):243-248. 

In This Article

Ovarian Cancer

Among survivors of epithelial ovarian cancer who have undergone bilateral oophorectomy, there is a role for HT for the management of menopausal symptoms. According to a recent systematic review and meta-analysis by Li et al[49] evaluating approximately 1,500 women with history of epithelial ovarian cancer treated surgically, HT use did not lead to a significant increase in risk of recurrence (RR 0.83, 95% CI 0.64–1.07) or death compared to non-users. These findings were consistent in subgroup analysis controlling for study design, stage, and grade of epithelial ovarian cancer.[49] In contrast, there are very limited data regarding the use of HT in women with history of ovarian cancer types that are likely to contain estrogen receptors (eg, granulosa cell, low-grade serous, and Sertoli-Leydig) given potential increased risk of recurrence.[17]

According to the North American Menopause Society 2017 position statement, there is no increase in the risk of recurrence or death in women receiving HT after surgical treatment for epithelial ovarian cancer. HT administration to women with histologic subtypes that are, however, likely to contain estrogen receptors (eg, granulosa cell, low-grade serous, and Sertoli-Leydig) is not currently recommended.[17]

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....